Cystic fibrosis (CF) lung disease is nowadays appreciated as a complex trait, characterised by
dysfunction of the CF Transmembrane Conductor (CFTR) protein, opportunistic bacterial infections,
chronic inflammation and remodelling of the airways. In this review, we have analysed the usefulness
of biomarkers of inflammation and remodelling for their ability in predicting and assessing the onset of
a pulmonary exacerbation, its evolution with time and its response to therapeutic interventions. Studies
concerning sputum, bronchoalveolar lavage fluid, exhaled breath condensate and blood were considered.
Our conclusions are: I) although their validity has been proven across different clinical settings,
presently there is no biomarker which can be “promoted” to the status of surrogate end-point; II) longitudinal
studies at different ages will be needed for assessing this issue; and III) different therapies
should consider not only one biomarker but a constellation of them aiding in the evaluation of the complex
pathogenesis of CF lung disease.
Keywords: Bronchoalveolar lavage, cystic fibrosis, cytokines, exhaled breath condensate, growth factors, oxidative stress,
open access plus
Rights & PermissionsPrintExport